Approval · Notice of Compliance 36207 · 2025
OPUVIZ: Notice of Compliance 36207
Issued October 9, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36207
- Date
- October 9, 2025
- Company
- Samsung Bioepis Co., LtdIncheon, Incheon, Korea, Republic Of
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Other
Products in this notice
Medicinal ingredients
- AFLIBERCEPT 2 MG per 0.05ML
- AFLIBERCEPT 2 MG per VIAL